MedPath

Safety and efficacy of inhaled sodium nitrite in patients with persistent asthma

Phase 1
Completed
Conditions
Asthma
nitrite
asthma
Registration Number
TCTR20190222004
Lead Sponsor
Mahidol university
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
160
Inclusion Criteria

Patients with persistent asthma with informed consent.
The eligible patients have persistent asthmatic symptoms (wheezing, cough, or shortness of breath) for at least 6 months, and must be able to do lung function test or body plethysmography.

Exclusion Criteria

Patients with aspirin-induced asthma, exercise-induced asthma, history of bronchopulmonary dysplasia, smoking, fixed airflow obstruction determined by spirometry, any other serious respiratory diseases other than asthma, acute asthma exacerbation or respiratory tract infection within 4 weeks of visit 1, frequent use of albuterol as rescue medication (> 6 MDI puffs per day or > 3 nebulized treatment per day on more than 2 consecutive days), hypersensitivity to sodium nitrite or any components in the inhalation solution, any history of heart disease, any malignancy, narrow-angle glaucoma, moderate-to-severe renal impairment, unwilling to enroll or withdraw consent at any time of the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in Changes in FEV1 from time zero, at times 0, 30, 60, 120, 180 min and 12 week after nebulization Body sphlegnography,Adverse events from sodium nitrite from time zero, at times 0, 30, 60, 120, 180 min, 4 week, 8 week and 12 week after nebulization Dizziness, flushing
Secondary Outcome Measures
NameTimeMethod
Monitored clinical 0, 4, 8,12 wk Asthma Control Test (ACT),Change in exhaled NO (FENO) from time zero, at times 5, 30, 45, and 60 min after nebulization Chemiluminescence,Change in systolic blood pressure, heart rate, oxygen saturation from time zero, at times 0, 30, 60, 120, 180 min, 4 week, 8 week and 12 week after nebulization Blood pressure, HR, O2 saturation measurement,Change in methemoglobin in venous blood From time zero and at times 120 min after nebulization Spectrophotometry,Renal clearance of nitrite from time zero to 120 min after nebulization Urinary nitrite by chemiluminescence,Change in platelet activity from times zero, at time 0, 60 min after nebulization Flow cytometry,Change in air trapping from time zero, at times 0, 30, 60, 120, 180 min and 12 week after nebulization Body sphlegnography
Âİ Copyright 2025. All Rights Reserved by MedPath